CLAIMS

WHAT IS CLAIMED IS:

1. Use of an effective dose of 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate (Compound 1), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating inflammation or neuropathic pain in a patient in need thereof, wherein the effective dose is from about 1 mg to about 500 mg.
2. Use of an effective dose of 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate (Compound 1), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating Epilepsy/Seizure Disorder, Multiple Sclerosis, Neuromyelitis Optica (NMO), Tourette Syndrome, Alzheimer Disease, or abdominal pain associated with Irritable Bowel Syndrome in a patient in need thereof, wherein the effective dose is from about 1 mg to about 100 mg.
3. Use of an effective dose of 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate (Compound 1), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating acute pain, inflammatory pain, cancer pain, pain caused by peripheral neuropathy, central pain, fibromyalgia, migraine, vasoocclussive painful crises in sickle cell disease, spasticity or pain associated with multiple sclerosis, functional chest pain, rheumatoid arthritis, osteoarthritis, or functional dyspepsia in a patient in need thereof, wherein the effective dose is from about 1 mg to about 100 mg.
4. Use of an effective dose of 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate (Compound 1), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating inflammation or neuropathic pain in a patient in need thereof, wherein a fragment of Compound 1 is covalently attached to at least 30% of MGLL in PBMCs from the patient after administration of the effective dose.
5. Use of an effective dose of 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate (Compound 1), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating inflammation or neuropathic pain in a patient in need thereof, wherein the plasma $AUC_{0\text{-}inf}$ of Compound 1 is at least 0.05 μM•hr after administration of the effective dose.

6. Use of an effective dose of 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate (Compound 1), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating inflammation or neuropathic pain in a patient in need thereof, wherein the steady state plasma $AUC_{0\text{-}inf}$ of Compound 1 is at least 0.05 μM•hr after administration of the effective dose.
7. The use of claim 4, wherein a fragment of Compound 1 is covalently attached to at least 40% of MGLL in PBMCs from the patient after administration of the effective dose.
8. The use of claim 4, wherein a fragment of Compound 1 is covalently attached to at least 50% of MGLL in PBMCs from the patient after administration of the effective dose
9. The use of claim 4, wherein a fragment of Compound 1 is covalently attached to at least 60% of MGLL in PBMCs from the patient after administration of the effective dose.
10. The use of claim 4, wherein a fragment of Compound 1 is covalently attached to at least 70% of MGLL in PBMCs from the patient after administration of the effective dose.
11. The use of claim 4, wherein a fragment of Compound 1 is covalently attached to at least 80% of MGLL in PBMCs from the patient after administration of the effective dose.
12. The use of claim 4, wherein a fragment of Compound 1 is covalently attached to at least 90% of MGLL in PBMCs from the patient after administration of the effective dose.
13. The use of any one of claims 4 and 7-12, wherein measurement of fragments of Compound 1 covalently attached to MGLL in PBMCs from the patient is performed using an *in vitro* assay.
14. The use of claim 5, wherein the plasma $AUC_{0\text{-}inf}$ of Compound 1 is at least 0.1 μM•hr after administration of the effective dose.
15. The use of claim 5, wherein the plasma $AUC_{0\text{-}inf}$ of Compound 1 is at least 0.2 μM•hr after administration of the effective dose.
16. The use of claim 5, wherein the plasma $AUC_{0\text{-}inf}$ of Compound 1 is at least 0.3 μM•hr after administration of the effective dose.

17. The use of claim 5, wherein the plasma $AUC_{0\text{-}inf}$ of Compound 1 is at least 0.4 μM•hr after administration of the effective dose.
18. The use of claim 5, wherein the plasma $AUC_{0\text{-}inf}$ of Compound 1 is at least 0.5 μM•hr after administration of the effective dose.
19. The use of claim 5, wherein the plasma $AUC_{0\text{-}inf}$ of Compound 1 is at least 0.6 μM•hr after administration of the effective dose.
20. The use of claim 5, wherein the plasma $AUC_{0\text{-}inf}$ of Compound 1 is at least 0.7 μM•hr after administration of the effective dose.
21. The use of claim 5, wherein the plasma $AUC_{0\text{-}inf}$ of Compound 1 is at least 0.8 μM•hr after administration of the effective dose.
22. The use of claim 6, wherein the steady state plasma $AUC_{0\text{-}inf}$ of Compound 1 is at least 0.1 μM•hr after administration of the effective dose.
23. The use of claim 6, wherein the steady state plasma $AUC_{0\text{-}inf}$ of Compound 1 is at least 0.2 μM•hr after administration of the effective dose.
24. The use of claim 6, wherein the steady state plasma $AUC_{0\text{-}inf}$ of Compound 1 is at least 0.3 μM•hr after administration of the effective dose.
25. The use of claim 6, wherein the steady state plasma $AUC_{0\text{-}inf}$ of Compound 1 is at least 0.4 μM•hr after administration of the effective dose.
26. The use of claim 6, wherein the steady state plasma $AUC_{0\text{-}inf}$ of Compound 1 is at least 0.5 μM•hr after administration of the effective dose.
27. The use of claim 6, wherein the steady state plasma $AUC_{0\text{-}inf}$ of Compound 1 is at least 0.6 μM•hr after administration of the effective dose.
28. The use of claim 6, wherein the steady state plasma $AUC_{0\text{-}inf}$ of Compound 1 is at least 0.7 μM•hr after administration of the effective dose.
29. The use of claim 6, wherein the steady state plasma $AUC_{0\text{-}inf}$ of Compound 1 is at least 0.8 μM•hr after administration of the effective dose.
30. The use of any one of claims 4-29, wherein the effective dose is from about 1 mg to about 500 mg.
31. The use of any one of claims 1 and 4-29, wherein the effective dose is from about 2 mg to about 400 mg.
32. The use of any one of claims 1 and 4-29, wherein the effective dose is from about 10 mg to about 160 mg.
33. The use of any one of claims 1-29, wherein the effective dose is from about 2 mg to about 100 mg.

34. The use of any one of claims 1-29, wherein the effective dose is from about 2 mg to about 50 mg.
35. The use of any one of claims 1-29, wherein the effective dose is from about 2 mg to about 20 mg.
36. The use of any one of claims 1-35, wherein Compound 1 is to be administered orally.
37. The use of claim 36, wherein the effective dose is to be taken with food.
38. The use of claim 36, wherein the effective dose is to be taken without food.
39. The use of any one of claims 1-38, wherein the effective dose is to be administered to the patient once per day.
40. The use of any one of claims 1-38, wherein the effective dose is to be administered to the patient twice per day.
41. Use of a composition comprising 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate (Compound 1), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating inflammation or neuropathic pain in a patient in need thereof, wherein administration of the composition provides a plasma $AUC_{0\text{-}inf}$ of at least 0.05 μM•hr.
42. The use of claim 41, wherein administration of the composition provides a plasma $AUC_{0\text{-}inf}$ of at least 0.1 μM•hr.
43. The use of claim 41, wherein wherein administration of the composition provides a plasma $AUC_{0\text{-}inf}$ of at least 0.2 μM•hr.
44. Use of a composition comprising 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate (Compound 1), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating Epilepsy/Seizure Disorder, Multiple Sclerosis, Neuromyelitis Optica (NMO), Tourette Syndrome, Alzheimer Disease, or abdominal pain associated with Irritable Bowel Syndrome in a patient in need thereof , wherein administration of the composition provides a plasma $AUC_{0\text{-}inf}$ of at least 0.05 μM•hr.
45. The use of claim 44, wherein administration of the composition provides a plasma $AUC_{0\text{-}inf}$ of at least 0.1 μM•hr.
46. The use of claim 44, wherein wherein administration of the composition provides a plasma $AUC_{0\text{-}inf}$ of at least 0.2 μM•hr.
47. Use of a composition comprising 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate (Compound 1), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for

treating acute pain, inflammatory pain, cancer pain, pain caused by peripheral neuropathy, central pain, fibromyalgia, migraine, vasoocclussive painful crises in sickle cell disease, spasticity or pain associated with multiple sclerosis, functional chest pain, rheumatoid arthritis, osteoarthritis, or functional dyspepsia in a patient in need thereof, wherein administration of the composition provides a plasma $AUC_{0\text{-}inf}$ of at least 0.05 μM•hr.

48. Use of a composition comprising 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate (Compound 1), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating inflammation or neuropathic pain in a patient in need thereof, wherein administration of the composition provides at least 30% of MGLL in PBMCs from the patient to be covalently attached to a fragment of Compound 1.
49. Use of a composition comprising 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate (Compound 1), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating Epilepsy/Seizure Disorder, Multiple Sclerosis, Neuromyelitis Optica (NMO), Tourette Syndrome, Alzheimer Disease, or abdominal pain associated with Irritable Bowel Syndrome in a patient in need thereof, wherein administration of the composition provides at least 30% of MGLL in PBMCs from the patient to be covalently attached to a fragment of Compound 1.
50. The use of any one of claims 40-49, wherein Compound 1 is to be administered orally.
51. A 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate (Compound 1) , or a pharmaceutically acceptable salt thereof, for use in binding MGLL in PBMCs in a subject, wherein a fragment of Compound 1 is covalently attached to at least 30% MGLL in PBMCs.
52. The compound for use according to claim 51, wherein a fragment of Compound 1 is covalently attached to at least 40% of MGLL in PBMCs from the subject after administration of the effective dose.
53. The compound for use according to claim 51, wherein a fragment of Compound 1 is covalently attached to at least 50% of MGLL in PBMCs from the subject after administration of the effective dose.

54. The compound for use according to claim 51, wherein a fragment of Compound 1 is covalently attached to at least 60% of MGLL in PBMCs from the subject after administration of the effective dose.
55. The compound for use according to claim 51, wherein a fragment of Compound 1 is covalently attached to at least 70% of MGLL in PBMCs from the subject after administration of the effective dose.
56. The compound for use according to claim 51, wherein a fragment of Compound 1 is covalently attached to at least 80% of MGLL in PBMCs from the subject after administration of the effective dose.
57. The compound for use according to claim 51, wherein a fragment of Compound 1 is covalently attached to at least 90% of MGLL in PBMCs from the subject after administration of the effective dose.
58. The compound for use according to any one of claims 51-57, wherein the effective dose is from about 1 mg to about 500 mg.
59. The compound for use according to any one of claims 51-57, wherein the effective dose is from about 2 mg to about 400 mg.
60. The compound for use according to any one of claims 51-57, wherein the effective dose is from about 10 mg to about 160 mg.
61. The compound for use according to any one of claims 51-57, wherein the effective dose is from about 2 mg to about 100 mg.
62. The compound for use according to any one of claims 51-57, wherein the effective dose is from about 2 mg to about 50 mg.
63. The compound for use according to any one of claims 51-57, wherein the effective dose is from about 2 mg to about 20 mg.
64. The compound for use according to any one of claims 51-63, wherein Compound 1 is to be administered orally.
65. A pharmaceutical composition for the treatment of inflammation or neuropathic pain, wherein the pharmaceutical composition comprises an effective dose of 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate (Compound 1), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the effective dose is from about 1 mg to about 500 mg.
66. The pharmaceutical composition of claim 65, wherein the effective dose is from about 2 mg to about 400 mg.

67. The pharmaceutical composition of claim 65, wherein the effective dose is from about 10 mg to about 160 mg.
68. The pharmaceutical composition of claim 65, wherein the effective dose is from about 2 mg to about 100 mg.
69. The pharmaceutical composition of claim 65, wherein the effective dose is from about 2 mg to about 50 mg.
70. The pharmaceutical composition of claim 65, wherein the effective dose is from about 2 mg to about 20 mg.
71. A pharmaceutical composition for the treatment of Epilepsy/Seizure Disorder, Multiple Sclerosis, Neuromyelitis Optica (NMO), Tourette Syndrome, Alzheimer Disease, or abdominal pain associated with Irritable Bowel Syndrome, wherein the pharmaceutical composition comprises an effective dose of 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate (Compound 1), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the effective dose is from about 1 mg to about 100 mg.
72. A pharmaceutical composition for the treatment of acute pain, inflammatory pain, cancer pain, pain caused by peripheral neuropathy, central pain, fibromyalgia, migraine, vasoocclussive painful crises in sickle cell disease, spasticity or pain associated with multiple sclerosis, functional chest pain, rheumatoid arthritis, osteoarthritis, or functional dyspepsia, wherein the pharmaceutical composition comprises an effective dose of 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate (Compound 1), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the effective dose is from about 1 mg to about 100 mg.
73. The pharmaceutical composition of claim 71 or claim 72, wherein the effective dose is from about 2 mg to about 100 mg.
74. The pharmaceutical composition of claim 71 or claim 72, wherein the effective dose is from about 2 mg to about 50 mg.
75. The pharmaceutical composition of claim 71 or claim 72, wherein the effective dose is from about 2 mg to about 20 mg.